Loading...
XTSX
COV
Market cap77mUSD
Oct 08, Last price  
3.99CAD
1D
4.45%
1Q
90.00%
Jan 2017
130.64%
IPO
-85.75%
Name

Covalon Technologies Ltd

Chart & performance

D1W1MN
XTSX:COV chart
P/E
53.54
P/S
3.36
EPS
0.07
Div yield, %
3.76%
Shrs. gr., 5y
1.56%
Rev. gr., 5y
4.93%
Revenues
33m
+5.29%
938,8001,285,6732,472,9782,285,5253,231,0672,588,0253,793,4514,134,1439,061,3297,588,7216,711,00827,309,75726,723,34234,004,62225,800,10619,561,30118,146,39026,595,28631,168,53232,816,347
Net income
2m
-22.91%
-2,204,990-3,076,377-3,740,847-4,874,809-3,934,947-3,561,941-3,991,382-993,1672,401,769-941,990-3,095,1481,811,6941,617,648-9,137,773-6,952,22423,476,906-9,663,213-4,460,9982,669,7922,058,089
CFO
2m
-34.09%
-2,322,817-146,210-2,763,587-4,668,210-58,201-3,324,379-3,274,070-1,485,9493,102,488-2,268,116-1,025,80815,147-655,470-2,825,479-4,025,441621,366-7,993,570-3,184,0083,472,9852,289,206
Dividend
Nov 04, 20250.15 CAD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Covalon Technologies Ltd., a Canadian company based in Mississauga, innovates, develops, manufactures, and commercializes medical technologies and products globally. Its operations span major international markets, including North America, Europe, the Middle East, Asia, and Latin America, with licensing agreements in place. The company leverages three distinct proprietary technology platforms. Firstly, its collagen matrix platform underpins a family of products aimed at treating a variety of chronic and infected wounds, such as diabetic, pressure, and venous ulcers, as well as donor and graft sites, traumatic injuries healing by secondary intention, dehisced surgical wounds, and first- and second-degree burns. Secondly, an antimicrobial silicone adhesive platform is incorporated into pre- and post-surgical and vascular access products; these are specifically engineered to provide broad-spectrum antimicrobial protection by eliminating bacteria or yeast on contact. Thirdly, a unique medical coating platform employs a proprietary photo-polymerization process to generate active grafting sites, enabling the initiation and growth of new polymer chains directly on existing medical devices. Covalon's product portfolio, branded under "Covalon," encompasses advanced wound care dressings, surgical and peri-operative solutions, and infection management tools. These offerings reach a diverse clientele, including hospitals, specialized wound and burn centers, acute and long-term care facilities, home health care agencies, and physicians' offices, via a combination of direct sales and extensive third-party distribution networks.

Key people

Katie Martinovich
Interim Chief Financial Officer · since 2024
Ronald Hebert
Senior Vice President - Marketing · since 2022
Jason Gorel
Vice President - Finance · since 2024
Amir Boloor
Executive Chairman of the Board · since 2024
Brent Ashton
Chief Executive Officer, Director · since 2024
Kim Crooks
Chief Operating Officer, Director · since 2025
Martin Goldfarb
Director · since 2023
Abe Schwartz
Director · since 2020
Lead Independent Director · since 2023
Samantha Nutt
Independent Director · since 2022
Independent Director · since 2019
IPO date
Sep 03, 2004
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2025‑092024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT